The post Will Bitcoin price drop below $70K as $2.2B BTC options expiry looms? appeared on BitcoinEthereumNews.com. Bitcoin price fell to near $70,000 on FridayThe post Will Bitcoin price drop below $70K as $2.2B BTC options expiry looms? appeared on BitcoinEthereumNews.com. Bitcoin price fell to near $70,000 on Friday

Will Bitcoin price drop below $70K as $2.2B BTC options expiry looms?

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Bitcoin price fell to near $70,000 on Friday following a sharp rebound the previous day. A looming BTC options expiry event is now keeping investors on edge as the market anticipates potential volatility.

Summary

  • Bitcoin price has given up a portion of its gains from this week.
  • Over $2.22 billion worth of options set to expire today have spurred concerns around volatility. 
  • Bitcoin technicals remain bullish despite the current drawdown.

According to data from crypto.news, Bitcoin (BTC) price fell 4.5% to an intraday low of $70,177 on Friday morning Asian time before stabilizing around $70,400 at press time. The bellwether pulled back after facing rejection around $74,000, a key resistance level it had failed to break for over a month. 

Bitcoin price fell as investors began booking profits after climbing over 15% in the past 5 days. 

This came amid a broader risk-off environment triggered by the ongoing war between the U.S. and Iran, which has led energy prices to soar to multi-month highs. The military escalation has also triggered capital rotation into traditional safe-haven assets, which have seen relatively better performance amid the geopolitical uncertainty. 

Today, investor sentiment is being kept in check as $2.22 billion worth of Bitcoin option expiry is set to be settled on the Deribit exchange at 8:00 a.m. UTC. Over 31,500 Bitcoin open contracts are set to expire.

At press time, the put-to-call ratio was at 1.72, meaning put options or traders betting on Bitcoin to go lower far surpass the calls that are betting on a rise. The maximum pain level for BTC or the price at which most option contracts expire worthless stood at $69,000, just $1,400 short of the current spot price. 

Bitcoin expiring options | Source: Deribit

The maximum pain level, also known as the strike price, tends to pull spot prices towards the center around expiry. Therefore, there remains a high risk that Bitcoin price could pull back towards the $69,000 mark as options reach expiry. 

Bitcoin has failed to hold above $70,000 six times since the start of February, and losing this key psychological support once again could spook short-term traders who were betting on the current recovery rally.

Despite the concerns surrounding the massive options expiry today, BTC price charts have not yet shown signs of a breakdown. 

On the Bitcoin/USDT 24-hour chart, momentum indicators still portrayed a positive outlook at least in the short term. 

Bitcoin/USDT 24-hour price chart — March 6 | Source: crypto.news

Notably, the MACD line was pointing upwards, suggesting growing buying pressure for the bulls in comparison to the selling pressure exerted by bears. At the same time, the Relative Strength Index has also formed a bullish divergence with the price action. 

For now, bulls will be eyeing $72,000 as the next major resistance level to claim, a break above which could likely end its downtrend today. 

On the contrary, a move below the $70,000 support could pull BTC price to $69,000 and successively as low as $60,000 as the broader structure remains confined within a bearish flag pattern, which is considered one of the most negative formations in technical analysis.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Source: https://crypto.news/will-bitcoin-price-drop-below-70k-as-2-2b-btc-options-expiry-looms/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09